Across TCGA pan-cancer cohorts, DIO3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DIO3 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher DIO3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DIO3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, ESCA, and UCEC are the cancer types where DIO3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	III,IV	0.348	0.686	.001	18	view →
ESCA	DFS	Median	II,III,IV	0.172	0.525	.015	9	view →
UCEC	DFS	Median	II,III,IV	0.933	0.436	.019	8	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: DIO3 tumor-vs-normal RNA expression · all DIO3 data types